FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761502562> ?p ?o ?g. }

• W2761502562 endingPage "96102" @default.
• W2761502562 startingPage "96089" @default.
• W2761502562 abstract "// Xi Chen 1 , Chun Xie 1 , Xing-Xing Fan 1 , Ze-Bo Jiang 1 , Vincent Kam-Wai Wong 1 , Jia-Hui Xu 1 , Xiao-Jun Yao 1 , Liang Liu 1 and Elaine Lai-Han Leung 1, 2, 3 1 State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, China 2 Respiratory Medicine Department, Taihe Hospital, Hubei University of Medicine, Hubei, China 3 Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, The 1st Affiliated Hospital of Guangzhou Medical College, Guangzhou, China Correspondence to: Elaine Lai-Han Leung, email: lhleung@must.edu.mo Xiao-Jun Yao, email: xjyao@must.edu.mo Liang Liu, email: lliu@must.edu.mo keywords: novel AMPK activator; NSCLC; gefitinib-resistant; lipid metabolism Received: June 27, 2017     Accepted: August 23, 2017     Published: October 09, 2017 ABSTRACT Drug resistance is becoming an obstacle in anti-cancer therapies. For target-based therapy of lung cancer, gefitinib, as the first generation of tyrosine kinase inhibitors (TKIs), demonstrated good initial response to the non-small cell lung cancer (NSCLC) patients whom harbors epidermal growth factor receptor (EGFR) mutation. However, within one year, additional EGFR mutation occurred, leading to eventual gefitinib-resistance. Therefore, it is urgently to discover novel effective small molecule inhibitors for those patients. Abnormal energy metabolism is accepted as new cancer hallmark. Recently, a metabolism rate-limiting enzyme 5’-adenosine menophosphate-activated protein kinase (AMPK) has become a promising anti-cancer target. In this study, we have identified a novel direct AMPK agonist, D561-0775 from a compound library by using molecular docking screening technique. We demonstrated that D561-0775 exhibited significant inhibitory effect on gefitinib-resistant NSCLC cell lines but less cytotoxicity on normal cells. Furthermore, D561-0775 demonstrated a remarkable in vitro AMPK enzyme activation effect. Taken together, D561-0775 showed potential anti-cancer activity via inducing apoptosis, cell cycle arrest, suppressing glycolysis and cholesterol synthesis after activation of AMPK in gefitinib-resistant H1975 cells. D561-0775 has provided a new chemical structure that could be developed as cancer drug for gefitinib-resistant NSCLC patients through inhibition lipid metabolism by directly targeting at AMPK directly." @default.
• W2761502562 created "2017-10-20" @default.
• W2761502562 creator A5000845924 @default.
• W2761502562 creator A5003554962 @default.
• W2761502562 creator A5008171524 @default.
• W2761502562 creator A5018785079 @default.
• W2761502562 creator A5037785133 @default.
• W2761502562 creator A5042284852 @default.
• W2761502562 creator A5066590728 @default.
• W2761502562 creator A5067592997 @default.
• W2761502562 creator A5087136994 @default.
• W2761502562 date "2017-10-09" @default.
• W2761502562 modified "2023-10-15" @default.
• W2761502562 title "Novel direct AMPK activator suppresses non-small cell lung cancer through inhibition of lipid metabolism" @default.
• W2761502562 cites W1523693806 @default.
• W2761502562 cites W1565979608 @default.
• W2761502562 cites W1837897049 @default.
• W2761502562 cites W1859037964 @default.
• W2761502562 cites W1965041207 @default.
• W2761502562 cites W1965927487 @default.
• W2761502562 cites W1967580058 @default.
• W2761502562 cites W1968881729 @default.
• W2761502562 cites W1970205234 @default.
• W2761502562 cites W1971766707 @default.
• W2761502562 cites W1972594681 @default.
• W2761502562 cites W1978679812 @default.
• W2761502562 cites W1978763812 @default.
• W2761502562 cites W1981744638 @default.
• W2761502562 cites W1982047458 @default.
• W2761502562 cites W1983890824 @default.
• W2761502562 cites W2000054651 @default.
• W2761502562 cites W2001532725 @default.
• W2761502562 cites W2005912218 @default.
• W2761502562 cites W2006691847 @default.
• W2761502562 cites W2010238890 @default.
• W2761502562 cites W2011239505 @default.
• W2761502562 cites W2011735982 @default.
• W2761502562 cites W2013895184 @default.
• W2761502562 cites W2019683289 @default.
• W2761502562 cites W2020809494 @default.
• W2761502562 cites W2022101765 @default.
• W2761502562 cites W2023947368 @default.
• W2761502562 cites W2024156773 @default.
• W2761502562 cites W2026413615 @default.
• W2761502562 cites W2035651268 @default.
• W2761502562 cites W2042844479 @default.
• W2761502562 cites W2046946656 @default.
• W2761502562 cites W2053201029 @default.
• W2761502562 cites W2059499603 @default.
• W2761502562 cites W2063690459 @default.
• W2761502562 cites W2064127449 @default.
• W2761502562 cites W2067979493 @default.
• W2761502562 cites W2071975518 @default.
• W2761502562 cites W2072362263 @default.
• W2761502562 cites W2072451938 @default.
• W2761502562 cites W2073534977 @default.
• W2761502562 cites W2076572520 @default.
• W2761502562 cites W2076908467 @default.
• W2761502562 cites W2077538477 @default.
• W2761502562 cites W2079580613 @default.
• W2761502562 cites W2080481362 @default.
• W2761502562 cites W2089448176 @default.
• W2761502562 cites W2089878663 @default.
• W2761502562 cites W2097259163 @default.
• W2761502562 cites W2101142723 @default.
• W2761502562 cites W2101428185 @default.
• W2761502562 cites W2102891343 @default.
• W2761502562 cites W2104366204 @default.
• W2761502562 cites W2106787323 @default.
• W2761502562 cites W2106823075 @default.
• W2761502562 cites W2108468164 @default.
• W2761502562 cites W2111352469 @default.
• W2761502562 cites W2111999353 @default.
• W2761502562 cites W2117630883 @default.
• W2761502562 cites W2122081799 @default.
• W2761502562 cites W2129585918 @default.
• W2761502562 cites W2134964552 @default.
• W2761502562 cites W2140805825 @default.
• W2761502562 cites W2145958122 @default.
• W2761502562 cites W2147645577 @default.
• W2761502562 cites W2153607816 @default.
• W2761502562 cites W2158535250 @default.
• W2761502562 cites W2159664830 @default.
• W2761502562 cites W2170095317 @default.
• W2761502562 cites W2170704593 @default.
• W2761502562 cites W2272984102 @default.
• W2761502562 cites W2282507274 @default.
• W2761502562 cites W2413970787 @default.
• W2761502562 cites W2482851537 @default.
• W2761502562 cites W394855183 @default.
• W2761502562 cites W798382597 @default.
• W2761502562 doi "https://doi.org/10.18632/oncotarget.21716" @default.
• W2761502562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5707083" @default.
• W2761502562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29221189" @default.
• W2761502562 hasPublicationYear "2017" @default.
• W2761502562 type Work @default.
• W2761502562 sameAs 2761502562 @default.
• W2761502562 citedByCount "19" @default.

• next